Drug combination for advanced ER-positive, HER2-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that tests positive for hormone receptors (ER/PR) and tests negative for HER2.
- Your cancer has spread (metastatic) or come back locally in a way that can’t be removed with surgery.
- Your disease has grown or progressed after treatment that included a CDK4/6 medicine, and you have also progressed on fulvestrant.
- You can take medicines by mouth, and you have no major uncontrolled health problems; basic blood and organ tests must be acceptable.
- You are able to use effective birth control during the study and for a period after treatment ends (pregnancy is not allowed).
- You have not had certain recent treatments (chemo/immunotherapy within 21 days, endocrine/biologic drugs within 14 days, and radiation or major surgery within 14 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The treatment combines fulvestaciclib (a CDK4/6 inhibitor) with anti-HER2 therapy and endocrine therapy, aiming to slow or stop cancer growth. It may be an option if you have not yet had treatment for advanced disease.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.